Table 5.
Secondary Outcomes
| Clinical Status | Placebo (n = 20) | Crizanlizumab (n = 22) |
|---|---|---|
| WHO status: day 3 | ||
| ≤3 (discharged) | 2 (10) | 3 (14) |
| 4 | 7 (35) | 3 (14) |
| 5 | 7 (35) | 13 (59) |
| 6 | 4 (20) | 3 (14) |
| WHO status: day 7 | ||
| ≤3 (discharged) | 13 (65) | 9 (41) |
| 4 | 3 (15) | 5 (23) |
| 5 | 3 (15) | 6 (27) |
| 6 | 1 (5) | 1 (5) |
| 7 | 0 (0) | 1 (5) |
| WHO status: day 14 | ||
| ≤3 (discharged) | 19 (95) | 21 (95) |
| 6 | 0 (0) | 1 (5) |
| 8 | 1 (5) | 0 (0) |
| Days in hospital | ||
| Admission to randomization | 1.5 ± 0.9 | 1.7 ± 1.4 |
| Randomization to discharge | 4.8 ± 3.5 | 6.5 ± 4.1 |
| Admission to discharge | 6.2 ± 3.2 | 8.1 ± 4.4 |
Values are n (%) or mean ± SD. Clinical outcomes were measured by the WHO Clinical Scale and length of hospital stay.
WHO = World Health Organization.